Drugs / Best Available Treatment
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07623200 | Jul 2026 → Jun 2029 expected | essential thrombocythemia | Incyte Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Best Available Treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623200 ↗ |